Under the terms of the agreement, entered into in December 2005, the companies are collaborating to discover and develop novel Nanobody-based therapeutics against disease targets that are difficult
hPAM4 is a humanized monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancer, but not pancreatitis, normal pancreas or most other normal tissues.
Medicis markets Solodyn for the treatment of moderate-to-severe acne. Impax and Medicis have previously entered into a settlement and license agreement, under which Impax has a license to
Under the terms of this agreement, RXi has the option, at its sole discretion, to sell to YA Global Investments newly issued common shares, subject to certain conditions,
The study is a randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, tolerability and efficacy of daily TT-223 treatments for 12 weeks with a six-month follow-up. Approximately
Approximately 48 healthy volunteers participated in the study, with 16 recruited for each of three dose groups. In each dose group, 12 volunteers received a single dose of
The primary objectives of this safety and tolerability study have been achieved. These were to determine the maximum tolerated dose and the dose-limiting toxicities for the agent when
Dyax has utilized phage display to generate on behalf of Biogen Idec high affinity, fully human antibody product candidates, including BIIB-022, currently in Phase I clinical trials for
The awarding of the patent thus allows to analyze by high-throughput processes to which extent such drug candidates block the export of viral messenger RNA from the cell
Each of the 39 separate Blue Cross and Blue Shield companies, acting independently, now has the opportunity to enter into an ancillary contract to access FAMILION LQTS tests
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.